ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global HIV Antivirals Market Research Report 2025
Published Date: 2025-12-23
|
Report Code: QYRE-Auto-10B18338
Home | Market Reports | Health| Reproductive Health
Global HIV Antivirals Market Research Report 2024
BUY CHAPTERS

Global HIV Antivirals Market Research Report 2025

Code: QYRE-Auto-10B18338
Report
2025-12-23
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Johnson & Johnson (Janssen Pharmaceuticals)
Merck
AbbVie
Bristol–Myers Squibb
Roche
Teva Pharmaceuticals

HIV Antivirals Market

The global market for HIV Antivirals was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
HIV antivirals are medications used to manage HIV infection by inhibiting the virus's ability to replicate and spread. They work by targeting different stages of the HIV life cycle. These drugs are often used in combination to effectively control the virus and improve the quality of life for people living with HIV.
North American market for HIV Antivirals is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for HIV Antivirals is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of HIV Antivirals include Gilead Sciences, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals), Merck & Co., AbbVie, Bristol-Myers Squibb, Roche, Teva Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for HIV Antivirals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Antivirals.
The HIV Antivirals market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global HIV Antivirals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HIV Antivirals manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of HIV Antivirals Market Report

Report Metric Details
Report Name HIV Antivirals Market
Segment by Type
  • Fixed Dose Combinations (FDCs)
  • Integrase Strand Transfer Inhibitors (lNSTls)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
  • Entry Inhibitors -CCR5 co-receptor antagonist
  • Protease Inhibitors (Pls)
  • Nucleoside Reverse Transcriptase lnhibitors (NRTls)
  • Others
Segment by Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Gilead Sciences, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals), Merck & Co., AbbVie, Bristol-Myers Squibb, Roche, Teva Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of HIV Antivirals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of HIV Antivirals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the HIV Antivirals Market report?

Ans: The main players in the HIV Antivirals Market are Gilead Sciences, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals), Merck & Co., AbbVie, Bristol-Myers Squibb, Roche, Teva Pharmaceuticals

What are the Application segmentation covered in the HIV Antivirals Market report?

Ans: The Applications covered in the HIV Antivirals Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the HIV Antivirals Market report?

Ans: The Types covered in the HIV Antivirals Market report are Fixed Dose Combinations (FDCs), Integrase Strand Transfer Inhibitors (lNSTls), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls), Entry Inhibitors -CCR5 co-receptor antagonist, Protease Inhibitors (Pls), Nucleoside Reverse Transcriptase lnhibitors (NRTls), Others

1 HIV Antivirals Market Overview
1.1 Product Definition
1.2 HIV Antivirals by Type
1.2.1 Global HIV Antivirals Market Value Comparison by Type (2024 VS 2031)
1.2.2 Fixed Dose Combinations (FDCs)
1.2.3 Integrase Strand Transfer Inhibitors (lNSTls)
1.2.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
1.2.5 Entry Inhibitors -CCR5 co-receptor antagonist
1.2.6 Protease Inhibitors (Pls)
1.2.7 Nucleoside Reverse Transcriptase lnhibitors (NRTls)
1.2.8 Others
1.3 HIV Antivirals by Application
1.3.1 Global HIV Antivirals Market Value by Application (2024 VS 2031)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global HIV Antivirals Market Size Estimates and Forecasts
1.4.1 Global HIV Antivirals Revenue 2020-2031
1.4.2 Global HIV Antivirals Sales 2020-2031
1.4.3 Global HIV Antivirals Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 HIV Antivirals Market Competition by Manufacturers
2.1 Global HIV Antivirals Sales Market Share by Manufacturers (2020-2025)
2.2 Global HIV Antivirals Revenue Market Share by Manufacturers (2020-2025)
2.3 Global HIV Antivirals Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of HIV Antivirals, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of HIV Antivirals, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of HIV Antivirals, Product Type & Application
2.7 Global Key Manufacturers of HIV Antivirals, Date of Enter into This Industry
2.8 Global HIV Antivirals Market Competitive Situation and Trends
2.8.1 Global HIV Antivirals Market Concentration Rate
2.8.2 The Global 5 and 10 Largest HIV Antivirals Players Market Share by Revenue
2.8.3 Global HIV Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global HIV Antivirals Market Scenario by Region
3.1 Global HIV Antivirals Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global HIV Antivirals Sales by Region: 2020-2031
3.2.1 Global HIV Antivirals Sales by Region: 2020-2025
3.2.2 Global HIV Antivirals Sales by Region: 2026-2031
3.3 Global HIV Antivirals Revenue by Region: 2020-2031
3.3.1 Global HIV Antivirals Revenue by Region: 2020-2025
3.3.2 Global HIV Antivirals Revenue by Region: 2026-2031
3.4 North America HIV Antivirals Market Facts & Figures by Country
3.4.1 North America HIV Antivirals Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America HIV Antivirals Sales by Country (2020-2031)
3.4.3 North America HIV Antivirals Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe HIV Antivirals Market Facts & Figures by Country
3.5.1 Europe HIV Antivirals Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe HIV Antivirals Sales by Country (2020-2031)
3.5.3 Europe HIV Antivirals Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HIV Antivirals Market Facts & Figures by Region
3.6.1 Asia Pacific HIV Antivirals Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific HIV Antivirals Sales by Region (2020-2031)
3.6.3 Asia Pacific HIV Antivirals Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America HIV Antivirals Market Facts & Figures by Country
3.7.1 Latin America HIV Antivirals Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America HIV Antivirals Sales by Country (2020-2031)
3.7.3 Latin America HIV Antivirals Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa HIV Antivirals Market Facts & Figures by Country
3.8.1 Middle East and Africa HIV Antivirals Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa HIV Antivirals Sales by Country (2020-2031)
3.8.3 Middle East and Africa HIV Antivirals Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global HIV Antivirals Sales by Type (2020-2031)
4.1.1 Global HIV Antivirals Sales by Type (2020-2025)
4.1.2 Global HIV Antivirals Sales by Type (2026-2031)
4.1.3 Global HIV Antivirals Sales Market Share by Type (2020-2031)
4.2 Global HIV Antivirals Revenue by Type (2020-2031)
4.2.1 Global HIV Antivirals Revenue by Type (2020-2025)
4.2.2 Global HIV Antivirals Revenue by Type (2026-2031)
4.2.3 Global HIV Antivirals Revenue Market Share by Type (2020-2031)
4.3 Global HIV Antivirals Price by Type (2020-2031)
5 Segment by Application
5.1 Global HIV Antivirals Sales by Application (2020-2031)
5.1.1 Global HIV Antivirals Sales by Application (2020-2025)
5.1.2 Global HIV Antivirals Sales by Application (2026-2031)
5.1.3 Global HIV Antivirals Sales Market Share by Application (2020-2031)
5.2 Global HIV Antivirals Revenue by Application (2020-2031)
5.2.1 Global HIV Antivirals Revenue by Application (2020-2025)
5.2.2 Global HIV Antivirals Revenue by Application (2026-2031)
5.2.3 Global HIV Antivirals Revenue Market Share by Application (2020-2031)
5.3 Global HIV Antivirals Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Gilead Sciences HIV Antivirals Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
6.2.4 ViiV Healthcare HIV Antivirals Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
6.3 Johnson & Johnson (Janssen Pharmaceuticals)
6.3.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Information
6.3.2 Johnson & Johnson (Janssen Pharmaceuticals) Description and Business Overview
6.3.3 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolio
6.3.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments/Updates
6.4 Merck & Co.
6.4.1 Merck & Co. Company Information
6.4.2 Merck & Co. Description and Business Overview
6.4.3 Merck & Co. HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Merck & Co. HIV Antivirals Product Portfolio
6.4.5 Merck & Co. Recent Developments/Updates
6.5 AbbVie
6.5.1 AbbVie Company Information
6.5.2 AbbVie Description and Business Overview
6.5.3 AbbVie HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
6.5.4 AbbVie HIV Antivirals Product Portfolio
6.5.5 AbbVie Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Company Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bristol-Myers Squibb HIV Antivirals Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Roche
6.7.1 Roche Company Information
6.7.2 Roche Description and Business Overview
6.7.3 Roche HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Roche HIV Antivirals Product Portfolio
6.7.5 Roche Recent Developments/Updates
6.8 Teva Pharmaceuticals
6.8.1 Teva Pharmaceuticals Company Information
6.8.2 Teva Pharmaceuticals Description and Business Overview
6.8.3 Teva Pharmaceuticals HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Teva Pharmaceuticals HIV Antivirals Product Portfolio
6.8.5 Teva Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HIV Antivirals Industry Chain Analysis
7.2 HIV Antivirals Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HIV Antivirals Production Mode & Process Analysis
7.4 HIV Antivirals Sales and Marketing
7.4.1 HIV Antivirals Sales Channels
7.4.2 HIV Antivirals Distributors
7.5 HIV Antivirals Customer Analysis
8 HIV Antivirals Market Dynamics
8.1 HIV Antivirals Industry Trends
8.2 HIV Antivirals Market Drivers
8.3 HIV Antivirals Market Challenges
8.4 HIV Antivirals Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Johnson & Johnson (Janssen Pharmaceuticals)
Merck
AbbVie
Bristol–Myers Squibb
Roche
Teva Pharmaceuticals
List of Tables
 Table 1. Global HIV Antivirals Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global HIV Antivirals Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global HIV Antivirals Market Competitive Situation by Manufacturers in 2024
 Table 4. Global HIV Antivirals Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global HIV Antivirals Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global HIV Antivirals Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global HIV Antivirals Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market HIV Antivirals Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of HIV Antivirals, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of HIV Antivirals, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of HIV Antivirals, Product Type & Application
 Table 12. Global Key Manufacturers of HIV Antivirals, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global HIV Antivirals by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Antivirals as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global HIV Antivirals Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global HIV Antivirals Sales by Region (2020-2025) & (K Units)
 Table 18. Global HIV Antivirals Sales Market Share by Region (2020-2025)
 Table 19. Global HIV Antivirals Sales by Region (2026-2031) & (K Units)
 Table 20. Global HIV Antivirals Sales Market Share by Region (2026-2031)
 Table 21. Global HIV Antivirals Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global HIV Antivirals Revenue Market Share by Region (2020-2025)
 Table 23. Global HIV Antivirals Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global HIV Antivirals Revenue Market Share by Region (2026-2031)
 Table 25. North America HIV Antivirals Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America HIV Antivirals Sales by Country (2020-2025) & (K Units)
 Table 27. North America HIV Antivirals Sales by Country (2026-2031) & (K Units)
 Table 28. North America HIV Antivirals Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America HIV Antivirals Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe HIV Antivirals Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe HIV Antivirals Sales by Country (2020-2025) & (K Units)
 Table 32. Europe HIV Antivirals Sales by Country (2026-2031) & (K Units)
 Table 33. Europe HIV Antivirals Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe HIV Antivirals Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific HIV Antivirals Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific HIV Antivirals Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific HIV Antivirals Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific HIV Antivirals Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific HIV Antivirals Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America HIV Antivirals Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America HIV Antivirals Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America HIV Antivirals Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America HIV Antivirals Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America HIV Antivirals Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa HIV Antivirals Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa HIV Antivirals Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa HIV Antivirals Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa HIV Antivirals Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa HIV Antivirals Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global HIV Antivirals Sales (K Units) by Type (2020-2025)
 Table 51. Global HIV Antivirals Sales (K Units) by Type (2026-2031)
 Table 52. Global HIV Antivirals Sales Market Share by Type (2020-2025)
 Table 53. Global HIV Antivirals Sales Market Share by Type (2026-2031)
 Table 54. Global HIV Antivirals Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global HIV Antivirals Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global HIV Antivirals Revenue Market Share by Type (2020-2025)
 Table 57. Global HIV Antivirals Revenue Market Share by Type (2026-2031)
 Table 58. Global HIV Antivirals Price (US$/Unit) by Type (2020-2025)
 Table 59. Global HIV Antivirals Price (US$/Unit) by Type (2026-2031)
 Table 60. Global HIV Antivirals Sales (K Units) by Application (2020-2025)
 Table 61. Global HIV Antivirals Sales (K Units) by Application (2026-2031)
 Table 62. Global HIV Antivirals Sales Market Share by Application (2020-2025)
 Table 63. Global HIV Antivirals Sales Market Share by Application (2026-2031)
 Table 64. Global HIV Antivirals Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global HIV Antivirals Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global HIV Antivirals Revenue Market Share by Application (2020-2025)
 Table 67. Global HIV Antivirals Revenue Market Share by Application (2026-2031)
 Table 68. Global HIV Antivirals Price (US$/Unit) by Application (2020-2025)
 Table 69. Global HIV Antivirals Price (US$/Unit) by Application (2026-2031)
 Table 70. Gilead Sciences Company Information
 Table 71. Gilead Sciences Description and Business Overview
 Table 72. Gilead Sciences HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Gilead Sciences HIV Antivirals Product
 Table 74. Gilead Sciences Recent Developments/Updates
 Table 75. ViiV Healthcare Company Information
 Table 76. ViiV Healthcare Description and Business Overview
 Table 77. ViiV Healthcare HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. ViiV Healthcare HIV Antivirals Product
 Table 79. ViiV Healthcare Recent Developments/Updates
 Table 80. Johnson & Johnson (Janssen Pharmaceuticals) Company Information
 Table 81. Johnson & Johnson (Janssen Pharmaceuticals) Description and Business Overview
 Table 82. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product
 Table 84. Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments/Updates
 Table 85. Merck & Co. Company Information
 Table 86. Merck & Co. Description and Business Overview
 Table 87. Merck & Co. HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Merck & Co. HIV Antivirals Product
 Table 89. Merck & Co. Recent Developments/Updates
 Table 90. AbbVie Company Information
 Table 91. AbbVie Description and Business Overview
 Table 92. AbbVie HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. AbbVie HIV Antivirals Product
 Table 94. AbbVie Recent Developments/Updates
 Table 95. Bristol-Myers Squibb Company Information
 Table 96. Bristol-Myers Squibb Description and Business Overview
 Table 97. Bristol-Myers Squibb HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Bristol-Myers Squibb HIV Antivirals Product
 Table 99. Bristol-Myers Squibb Recent Developments/Updates
 Table 100. Roche Company Information
 Table 101. Roche Description and Business Overview
 Table 102. Roche HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Roche HIV Antivirals Product
 Table 104. Roche Recent Developments/Updates
 Table 105. Teva Pharmaceuticals Company Information
 Table 106. Teva Pharmaceuticals Description and Business Overview
 Table 107. Teva Pharmaceuticals HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Teva Pharmaceuticals HIV Antivirals Product
 Table 109. Teva Pharmaceuticals Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. HIV Antivirals Distributors List
 Table 113. HIV Antivirals Customers List
 Table 114. HIV Antivirals Market Trends
 Table 115. HIV Antivirals Market Drivers
 Table 116. HIV Antivirals Market Challenges
 Table 117. HIV Antivirals Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of HIV Antivirals
 Figure 2. Global HIV Antivirals Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global HIV Antivirals Market Share by Type: 2024 & 2031
 Figure 4. Fixed Dose Combinations (FDCs) Product Picture
 Figure 5. Integrase Strand Transfer Inhibitors (lNSTls) Product Picture
 Figure 6. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls) Product Picture
 Figure 7. Entry Inhibitors -CCR5 co-receptor antagonist Product Picture
 Figure 8. Protease Inhibitors (Pls) Product Picture
 Figure 9. Nucleoside Reverse Transcriptase lnhibitors (NRTls) Product Picture
 Figure 10. Others Product Picture
 Figure 11. Global HIV Antivirals Market Value by Application (2020-2031) & (US$ Million)
 Figure 12. Global HIV Antivirals Market Share by Application: 2024 & 2031
 Figure 13. Hospital Pharmacies
 Figure 14. Retail Pharmacies
 Figure 15. Online Pharmacies
 Figure 16. Global HIV Antivirals Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global HIV Antivirals Market Size (2020-2031) & (US$ Million)
 Figure 18. Global HIV Antivirals Sales (2020-2031) & (K Units)
 Figure 19. Global HIV Antivirals Average Price (US$/Unit) & (2020-2031)
 Figure 20. HIV Antivirals Report Years Considered
 Figure 21. HIV Antivirals Sales Share by Manufacturers in 2024
 Figure 22. Global HIV Antivirals Revenue Share by Manufacturers in 2024
 Figure 23. Global 5 and 10 Largest HIV Antivirals Players: Market Share by Revenue in HIV Antivirals in 2024
 Figure 24. HIV Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 25. Global HIV Antivirals Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 26. North America HIV Antivirals Sales Market Share by Country (2020-2031)
 Figure 27. North America HIV Antivirals Revenue Market Share by Country (2020-2031)
 Figure 28. United States HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Canada HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Europe HIV Antivirals Sales Market Share by Country (2020-2031)
 Figure 31. Europe HIV Antivirals Revenue Market Share by Country (2020-2031)
 Figure 32. Germany HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. France HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. U.K. HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Italy HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Russia HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Asia Pacific HIV Antivirals Sales Market Share by Region (2020-2031)
 Figure 38. Asia Pacific HIV Antivirals Revenue Market Share by Region (2020-2031)
 Figure 39. China HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Japan HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. South Korea HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. India HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Australia HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. China Taiwan HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Southeast Asia HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America HIV Antivirals Sales Market Share by Country (2020-2031)
 Figure 47. Latin America HIV Antivirals Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Colombia HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Middle East and Africa HIV Antivirals Sales Market Share by Country (2020-2031)
 Figure 53. Middle East and Africa HIV Antivirals Revenue Market Share by Country (2020-2031)
 Figure 54. Turkey HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Saudi Arabia HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. UAE HIV Antivirals Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Global Sales Market Share of HIV Antivirals by Type (2020-2031)
 Figure 58. Global Revenue Market Share of HIV Antivirals by Type (2020-2031)
 Figure 59. Global HIV Antivirals Price (US$/Unit) by Type (2020-2031)
 Figure 60. Global Sales Market Share of HIV Antivirals by Application (2020-2031)
 Figure 61. Global Revenue Market Share of HIV Antivirals by Application (2020-2031)
 Figure 62. Global HIV Antivirals Price (US$/Unit) by Application (2020-2031)
 Figure 63. HIV Antivirals Value Chain
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions